Compare Stocks: BHVN, RYTM, CGON, and MIRM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$13.65 -8.1%	$14.38	$7.48 ▼ $18.57	$2.06B	1.28	2.73 million shs	2.74 million shs
CGON CG Oncology	$73.36 -5.6%	$74.30	$35.64 ▼ $80.97	$6.50B	0.24	1.10 million shs	830,942 shs
MIRM Mirum Pharmaceuticals	$89.32 -2.3%	$102.68	$63.23 ▼ $130.00	$5.80B	0.49	850,725 shs	739,007 shs
RYTM Rhythm Pharmaceuticals	$98.24 -1.0%	$106.85	$74.50 ▼ $122.20	$6.73B	1.97	755,283 shs	696,408 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	+4.48%	+20.66%	+6.74%	-0.47%	-0.46%
CGON CG Oncology	-0.65%	+7.15%	-2.59%	+13.13%	+109.88%
MIRM Mirum Pharmaceuticals	-0.66%	-2.67%	-5.11%	-20.37%	+23.62%
RYTM Rhythm Pharmaceuticals	+0.45%	+2.58%	-9.75%	-7.70%	+0.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$13.65 -8.1%	$14.38	$7.48 ▼ $18.57	$2.06B	1.28	2.73 million shs	2.74 million shs
CGON CG Oncology	$73.36 -5.6%	$74.30	$35.64 ▼ $80.97	$6.50B	0.24	1.10 million shs	830,942 shs
MIRM Mirum Pharmaceuticals	$89.32 -2.3%	$102.68	$63.23 ▼ $130.00	$5.80B	0.49	850,725 shs	739,007 shs
RYTM Rhythm Pharmaceuticals	$98.24 -1.0%	$106.85	$74.50 ▼ $122.20	$6.73B	1.97	755,283 shs	696,408 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	+4.48%	+20.66%	+6.74%	-0.47%	-0.46%
CGON CG Oncology	-0.65%	+7.15%	-2.59%	+13.13%	+109.88%
MIRM Mirum Pharmaceuticals	-0.66%	-2.67%	-5.11%	-20.37%	+23.62%
RYTM Rhythm Pharmaceuticals	+0.45%	+2.58%	-9.75%	-7.70%	+0.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHVN Biohaven	2.59	Moderate Buy	$18.69	36.94% Upside
CGON CG Oncology	2.73	Moderate Buy	$87.78	19.65% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$137.31	53.73% Upside
RYTM Rhythm Pharmaceuticals	2.76	Moderate Buy	$140.67	43.19% Upside

Current Analyst Ratings Breakdown

Latest BHVN, RYTM, CGON, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	BHVN Biohaven	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/17/2026	RYTM Rhythm Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/14/2026	RYTM Rhythm Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$133.00
9/10/2026	BHVN Biohaven	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$10.00
9/8/2026	BHVN Biohaven	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$23.00 ➝ $19.00
8/28/2026	BHVN Biohaven	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/28/2026	BHVN Biohaven	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$21.00
8/28/2026	RYTM Rhythm Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$120.00
8/27/2026	BHVN Biohaven	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/27/2026	MIRM Mirum Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$137.00
8/27/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.39 per share	N/A
CGON CG Oncology	$4.04M	1,609.56	N/A	N/A	$9.33 per share	7.86
MIRM Mirum Pharmaceuticals	$521.31M	11.12	$0.05 per share	1,804.66	$6.12 per share	14.59
RYTM Rhythm Pharmaceuticals	$189.76M	35.48	N/A	N/A	$2.08 per share	47.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHVN Biohaven	-$738.82M	-$4.64	N/A	N/A	N/A	N/A	-1,328.94%	-138.27%	11/9/2026 (Estimated)
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)

Latest BHVN, RYTM, CGON, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.91	-$0.1490	-$0.91	$0.49 million	N/A
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHVN Biohaven	21.23	4.73	4.73
CGON CG Oncology	N/A	22.22	22.20
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHVN Biohaven	88.78%
CGON CG Oncology	26.56%
MIRM Mirum Pharmaceuticals	N/A
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
BHVN Biohaven	13.80%
CGON CG Oncology	4.80%
MIRM Mirum Pharmaceuticals	8.32%
RYTM Rhythm Pharmaceuticals	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHVN Biohaven	274	151.04 million	130.20 million	Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
MIRM Mirum Pharmaceuticals	433	64.93 million	59.53 million	Optionable
RYTM Rhythm Pharmaceuticals	414	68.53 million	64.49 million	Optionable

BHVN, RYTM, CGON, and MIRM Headlines

Recent News About These Companies

Rhythm Pharmaceuticals, Inc. Announces Health Canada Approval Of IMCIVREE (Setmelanotide) For Weight Management In Adult And Pediatric Patients 4 Years Of Age And Older With ...

September 23 at 5:59 AM | marketscreener.comM

Health Canada approves Rhythm's Imcivree for hypothalamic obesity

September 23 at 5:59 AM | streetinsider.com

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with ...

September 22 at 8:47 AM | markets.businessinsider.com

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

September 22 at 8:00 AM | globenewswire.com

325,470 Shares in Rhythm Pharmaceuticals, Inc. $RYTM Acquired by Bank of America Corp DE

September 22 at 3:04 AM | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated at Wolfe Research

September 19, 2026 | americanbankingnews.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated by Analysts at Wolfe Research

September 17, 2026 | marketbeat.com

RBC Capital Reaffirms Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

September 17, 2026 | theglobeandmail.com

J.P. Morgan Remains a Buy on Rhythm Pharmaceuticals (RYTM)

September 17, 2026 | theglobeandmail.com

Wolfe Research Initiates Rhythm Pharmaceuticals at Outperform

September 17, 2026 | marketscreener.comM

Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Down 5.3% After Insider Selling

September 17, 2026 | americanbankingnews.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated at Leerink Partners

September 16, 2026 | americanbankingnews.com

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 5.3% on Insider Selling

September 15, 2026 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) CEO David Meeker Sells 50,000 Shares

September 15, 2026 | americanbankingnews.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) CEO Sells $5,133,500.00 in Stock

September 15, 2026 | insidertrades.com

Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) CEO Sells 50,000 Shares of Stock

September 14, 2026 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Now Covered by Analysts at Leerink Partners

September 14, 2026 | marketbeat.com

California State Teachers Retirement System Lowers Stake in Rhythm Pharmaceuticals, Inc. $RYTM

September 14, 2026 | marketbeat.com

Head-To-Head Survey: Generate Biomedicines (NASDAQ:GENB) vs. Rhythm Pharmaceuticals (NASDAQ:RYTM)

September 12, 2026 | americanbankingnews.com

Rhythm Pharmaceuticals Presents New Data on Setmelanotide Therapy and Phase 3 Analyses At European Society for Paediatric Endocrinology Meeting

September 11, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN, RYTM, CGON, and MIRM Company Descriptions

Biohaven NYSE:BHVN

$13.65 -1.20 (-8.11%)

Closing price 03:59 PM Eastern

Extended Trading

$13.78 +0.14 (+1.02%)

As of 06:34 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

CG Oncology NASDAQ:CGON

$73.36 -4.38 (-5.63%)

Closing price 04:00 PM Eastern

Extended Trading

$73.36 0.00 (-0.01%)

As of 04:54 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$89.32 -2.07 (-2.27%)

Closing price 04:00 PM Eastern

Extended Trading

$89.15 -0.17 (-0.19%)

As of 06:15 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Rhythm Pharmaceuticals NASDAQ:RYTM

$98.24 -1.03 (-1.04%)

Closing price 04:00 PM Eastern

Extended Trading

$97.34 -0.91 (-0.92%)

As of 06:53 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BHVN, RYTM, CGON, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BHVN, RYTM, CGON, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BHVN, RYTM, CGON, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN, RYTM, CGON, and MIRM Company Descriptions

Biohaven NYSE:BHVN

CG Oncology NASDAQ:CGON

Mirum Pharmaceuticals NASDAQ:MIRM

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BHVN, RYTM, CGON, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BHVN, RYTM, CGON, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BHVN, RYTM, CGON, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN, RYTM, CGON, and MIRM Company Descriptions

Biohaven NYSE:BHVN

CG Oncology NASDAQ:CGON

Mirum Pharmaceuticals NASDAQ:MIRM

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools